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ABSTRACT 
Pancreatic cancer is one of the most devastating malignancies with an extremely high fatality, 
resulting that its mortality rate almost equals to incidence rate. Although primary prevention 
is of upmost importance, the underlying etiology of this cancer remains largely unknown. 
Pancreatic cancer is a heterogenetic disease, and the accumulated genetic alterations play an 
important role in pancreatic pathogenesis. Recent advances in next-generation sequencing 
have enabled comprehensive cancer genomic studies. However, clinical pancreatic cancer 
samples are characterized as having low tumor cellularity, as a result of an abundance of 
stroma in the tumor microenvironment, and this presents a big challenge for direct genomic 
sequencing for clinical pancreatic cancer samples. In this thesis, we aimed to enrich our 
knowledge of the etiology of pancreatic cancer with regard to several infectious agents and 
poor oral hygiene. Of note, we took the challenge to directly sequence clinical pancreatic 
cancer samples with a broad range of tumor cellularities, and attempted to depict its variant 
profile. 
In Study I, we retrieved all hepatitis C virus (HCV) and hepatitis B virus (HBV) infection 
notifications in Sweden from records in a national surveillance database at the Swedish 
Institutet for Infectious Disease Control (SMI) from 1990 to 2006, and followed them for 
pancreatic cancer occurrence by the end of 2008. The pancreatic cancer risk in the exposed 
population was compared with that in a matched reference population. Hazard ratios (HRs) 
were derived from Cox proportional hazards regression models. The main finding in this 
study is that the subjects with HCV infection had a 60% increased risk after adjustment for 
potential confounders. Therefore, the finding implied that HCV infection may be associated 
with a higher pancreatic cancer risk but further studies are warranted to confirm the observed 
association. The point estimate in this study also suggested an excessive risk among subjects 
with HBV infection, however, without statistical significance due to a lack of study power.  
In Study II, we took advantage of the population-based prevalence study of oral mucosal 
lesions conducted in Uppsala County in central Sweden during 1973-74. The study 
population was followed through linkages with the Swedish population and health registers. 
A total of 19 924 participants were included in the final analysis, with 126 pancreatic cancer 
ascertained during an average of 28.7 years of follow-up. Among all tested indicators of poor 
oral hygiene, we found that fewer teeth at baseline appeared to increase pancreatic cancer 
risk, although the relative risk estimates were not statistically significant. Among the subjects 
with more than 10 teeth, subjects with unacceptable dental plaque had a doubled risk of 
pancreatic cancer compared with those without dental plaque after controlling for potential 
confounding factors. Subjects with Candida-related or denture-related oral mucosal lesions, 
or tongue lesions, compared with those without any of the three lesions, showed a 70%, 30% 
and 80% increased pancreatic cancer risk, respectively.  
In Study III, we carried out a nested case-control study within the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort, including 448 pancreatic cancer cases 
and their individually matched control subjects. We measured serum antibodies against 
Helicobacter pylori (H. pylori) and pepsinogens I and II (markers for presence of chronic 
corpus atrophic gastritis) by enzyme-linked immunosorbent assays. Conditional logistic 
regression models were used to estimate odds ratios (ORs). Overall, our results demonstrated 
that pancreatic cancer risk was neither associated with H. pylori seropositivity nor CagA 
seropositivity. On the other hand, our findings showed that presence of chronic corpus 
atrophic gastritis was non-significantly associated with an increased pancreatic cancer risk. 
Although based on small numbers, the association was particularly prominent among 
individuals seronegative for both H. pylori and CagA (OR=5.66; 95% confidence interval: 
1.59, 20.19; p value for interaction <0.01).  
In Study IV, we conducted a case-only study that sourced from a population-based case-
control study of pancreatic cancer in Stockholm, Sweden. This study included patients with 
pancreatic ductal adenocarcinoma (PDAC) who underwent resection surgery between 2007 
and 2012 (n=73). Patients were followed from diagnosis until death or the end of the study. 
We used an Anchored Multiplex Polymerase chain reaction (AMP)-based method for 
profiling variants in a panel of 65 selected genes. Our findings suggested that the AMP-based 
next-generation sequencing method can detect variants with allelic frequencies as low as 1% 
given sufficient sequencing depth. KRAS G12 mutations were completely confirmed by 
Sanger sequencing for high-allele-frequency samples (>5%), and also fully confirmed by 
allele-specific PCR and digital PCR for low-allele-frequency samples (1%-5%). The results 
demonstrated that KRAS mutant subtype G12V is related to a worse prognosis in PDAC 
patients, and transversion variants are more common among smokers.  
In conclusion, we found that HCV, as an infectious agent, may be associated with a higher 
pancreatic cancer risk. Our findings also support the hypothesis that poor oral hygiene plays a 
key role in the development of pancreatic cancer. On the other hand, we observed a null 
association between H. pylori infection and pancreatic cancer risk in the western European 
populations, but a suggested positive association between chronic corpus atrophic gastritis 
and pancreatic cancer risk based on a small sample size. Further studies are warranted to 
verify whether severe gastric atrophy contributes to pancreatic carcinogenesis. AMP-based 
next generation sequencing is a sensitive and accurate method for profiling tumor variants in 
PDAC. Future studies with larger sample sizes are needed to explore the role of tumor 
variants in PDAC prognosis and the impact of environmental risk factors on tumor 
mutational profile. 
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1 INTRODUCTION 
Pancreatic cancer is one of the most aggressive and devastating malignancies. Although 
considerable efforts have been made to prevent and cure this lethal disease, it still remains a 
major health burden worldwide, given its rapid progression, invasiveness and resistant to 
treatment. Due to its insidious onset, it is often diagnosed at an advanced stage, when curative 
surgery is no longer an option. Although pancreatic cancer is not a common malignancy, 
because of its high fatality rate, it ranks as the 4th or 5th most common cause of cancer-
related death in developed countries, such as in Europe (1, 2).  Established risk factors (3, 4) 
include advanced age, male sex, smoking, chronic pancreatitis, type 2 diabetes, central 
obesity and a family history of pancreatic cancer. However, it has been estimated in UK that 
the identified risk factors only account for approximately 40% of all pancreatic cancer cases 
(5). The etiology of pancreatic cancer remains unclear. Therefore further studies are urgently 
warranted to identify its risk factors, as well as to understand its genetic heterogeneity, given 
their key roles in the pancreatic carcinogenesis.  
Recent advances in next-generation sequencing (NGS) have enabled genetic architectural 
understanding of cancers, including pancreatic cancer. Pancreatic cancer is a heterogeneous 
disease at the molecular level, and results from successive accumulation of genetic mutations 
from distinct types of pancreatic precursor lesions, such as pancreatic intraepithelial neoplasia 
which is the most common type of precursor lesion. However, a major feature of pancreatic 
cancer is the formation of abundant stroma, termed as desmoplastic reaction. It presents a 
great challenge for genomic sequencing for this tumor owing to its low tumor cellularity and 
thus has limited earlier studies due to dilution of the tumor cells of interest present in an 
overwhelming wild-type background. Therefore, studies are merited particularly with regards 
to deep targeted sequencing method that may provide higher analytical sensitivity with a 
broader coverage for clinical samples.
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2 BACKGROUND 
2.1 DESCRIPTIVE EPIDEMIOLOGY OF PANCREATIC CANCER 
Pancreatic cancer is one of the most devastating malignancies. Its incidence ranges from 1 to 
10 cases per 100 000 person-year worldwide. The incidence of pancreatic cancer is generally 
higher in the developed countries than the developing countries. Globally in 2007 (6), the 
highest mortality rates for pancreatic cancer were in the Baltic countries (more than 9.5/100 
000 among men and 6/100 000 among women), whereas Latin America and Hong Kong had 
the lowest mortality rates (below 5/100 000 among men and 3/100 000 among women). The 
overall 5-year survival rate for pancreatic cancer patients is less than 5% (2, 7-9). Owing to 
its high fatality, pancreatic cancer ranks the 7th most common cause of cancer-related death 
throughout the world, and the 4th or the 5th in the developed countries, including Europe (2). 
Pancreatic cancer mortality rates were increasing in the developed countries from the 1950s 
to the 1980s, and leveled off or declined soon thereafter, especially in men. However, it is 
difficult to explain the secular trend, since the apparent increase might largely be interpreted 
as an improvement of diagnostic methods, rather than occurrence of more cases (10). 
Pancreatic cancer is more common in the old age population, and the median age at diagnosis 
is 71 years. Therefore, it has been estimated that the global burden of pancreatic cancer will 
increase given the improvement of life expectancy in the coming decades (3). For men, the 
cumulative probability of developing pancreatic cancer through lifetime is 1%, and slightly 
lower for women, given the fact that men have a higher smoking rate than women (10).  
2.2 CLINICAL ASPECTS OF PANCREATIC CANCER 
2.2.1 Symptoms 
The presenting symptoms of pancreatic cancer are largely determined by the location of the 
tumor in the pancreas, as well as the disease stage. Due to its insidious onset, pancreatic 
cancer often escapes from detection during its formative stage, and cannot be detected until 
an advanced stage, when a curative resection surgery is no longer possible. Approximately 60 
to 70% of pancreatic cancers present in the head of the gland, and result in obstructive 
cholestasis and jaundice. Common symptoms in pancreatic cancer patients include abdominal 
pain, weight loss, asthenia and anorexia (11).  
2.2.2 Diagnosis 
It has always been a challenge for the diagnosis of pancreatic cancer, owing to its deep 
location. Imaging technologies including computer tomography (CT) scan, magnetic 
resonance imaging (MRI), positron emission tomography (PET), endoscopic retrograde 
cholangiopancreatography (ERCP), as well as endoscopic ultrasound (EUS) are critical 
diagnostic tools for pancreatic cancer. Studies evaluating the diagnostic ability of endoscopic 
ultrasound, computed tomography, and MRI in patients suspected of harboring pancreatic 
cancer have revealed a sensitivity of 94%, 69%, and 83%, respectively (12). Among the 
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diagnostically uncertain cases, EUS-guided fine needle aspiration (FNA) should be further 
employed for cytological assessment; however, its effectiveness still requires further 
evaluation.   
As for potential serum biomarkers for diagnosis, carbohydrate antigen 19-9 (CA19-9) 
probably is the only biomarker with clinical application for the early detection or monitoring 
of recurrent disease (13-17). CA 19-9 is produced in the biliary cells, therefore the diseases 
that affect those cells will lead to elevation of serum CA 19-9, such as pancreatitis, cirrhosis 
and cholangitis (11). In addition, approximately 10% of the patients are unable to produce 
CA 19-9, with an undetectable level of CA 19-9 even in advanced stage of this disease (9). 
With the sensitivity of 80% and specificity of 73%, it is still premature to use this biomarker 
alone for a diagnostic purpose (18).    
2.2.3 Subtypes of pancreatic cancer 
Pancreatic cancer comprises exocrine and endocrine tumors (19). The exocrine pancreatic 
tumors are more common, accounting for approximately 95% of all pancreatic cancers, and 
encompass adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, giant cell 
tumor, intraductal papillary mucinous neoplasm (IPMN), mucinous cystadenocarcinoma, 
pancreatoblastoma, serous cystadenocarcinoma, solid and pseudopapillary tumors (11). Over 
85% of pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC). This thesis has an 
emphasis on exocrine pancreatic cancer, and Study IV focuses on the PDAC subtype only.  
2.3 RISK FACTORS 
A better understanding of the etiological factors is critical to identify high-risk groups, and 
for the prevention and early detection of the disease. A study in UK estimated that the current 
identified risk factors account for less than 40% of all pancreatic cancer cases. Instead of one 
dominant factor, multifactorial environmental factors are involved in contributing to 
pancreatic cancer development. To date, established risk factors for pancreatic cancer include 
advanced age (1), male sex (20), tobacco smoking (21-25), chronic pancreatitis (26, 27), type 
2 diabetes mellitus (21, 28-33), obesity (5, 34-38), a family history of pancreatic cancer (39-
42), non-O blood group (43, 44), heavy alcohol consumption (45-48), height (tallness) (21, 
49-52),  as well as high waist-to-hip ratio (49, 53). On the other hand, previous studies have 
indicated that allergy (54, 55), high adiponectin level (56), intense occupational physical 
activity (57, 58), and high dietary folate intake (59-62) may have a potentially protective 
effect against pancreatic cancer. The evidence for associations between several other factors 
and pancreatic cancer risk is less established, including nonsteroidal anti-inflammatory drugs 
(63-66), fish (67, 68), soft drinks (69, 70), coffee or tea (70-72), glycemic index or glycemic 
load (73, 74), and plasma 25(OH)D level (75-77). Other potential risk factors which have 
been examined but still need further confirmation, including idiopathic thrombosis (78) , 
Scandinavian moist snuff (79), history of gastrectomy (80), history of cholecystectomy (81), 
red meat (67, 82), processed meat (82),  elevated sugar intake (74) and psychological stress 
(83).   
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2.3.1 Hepatitis C virus (HCV) or hepatitis B virus (HBV) infection 
Approximately 170 and 350 million people are infected with HCV and HBV throughout the 
world (84, 85). The geographical variations for the prevalence of HCV or HBV infection are 
relatively large, ranging from less than 0.5% in Western countries, 7% in the East Asian, and 
up to 25% in the African countries (86, 87). As a low endemic country, it was estimated in 
Sweden that 0.5% of the population were infected with HCV, and even lower for HBV 
infection (88). Prior studies demonstrated that HBV was able to replicate within the pancreas 
gland (89, 90), and HCV infection was associated with pancreatitis (91, 92). The pancreas is a 
potential extrahepatic organ for inhabitation of the hepatitis virus, which makes it biological 
plausible that the HCV or HBV infection might be associated with an increased risk of 
pancreatic cancer. However such associations are still unclear and further studies are 
warranted, for a better understanding of the etiology of pancreatic cancer.  
2.3.2 Poor oral hygiene 
The oral cavity connects between the gastrointestinal tract and external environment. Poor 
oral hygiene, through oral microbiome alterations, may lead to a series of events, including 
dental plaque, periodontal disease and tooth loss (93). Loss of tooth may be used as a proxy 
of bacterial load on the teeth (93). Dental plaque is formed from bacterial biofilm that adheres 
to the surface of teeth. It was estimated that hundreds of bacterial species inhabit in the 
subgingival plaque. Although oral mucosal lesions are multifactorial diseases, the oral 
mucosal pathogens are considered as one of the most important etiologic risk factors. Poor 
oral hygiene has been previously proposed to be positively associated with pancreatic cancer 
risk in several epidemiologic studies (93-97). Three large cohort studies provided supportive 
evidence for the link between periodontal disease and pancreatic cancer risk (94, 95, 98). 
However, the findings were largely inconsistent for the association between tooth number 
and pancreatic cancer risk (98, 99). The aforementioned studies were based mostly on self-
reported oral hygiene indicators and only one study contained repeated measurement during 
follow-up.  In two studies with direct dental examination, the pancreatic cancer cases were 
ascertained from death certificate records, and the results were based on rather small case 
numbers (94, 95). Therefore, the association between poor oral hygiene and pancreatic cancer 
still awaits confirmation by larger cohort studies with detailed oral examinations.  
2.3.3 Helicobacter pylori (H. pylori) infection 
H. pylori has been identified as a group I carcinogen by IARC (100), and it is widely 
considered to play a crucial role in the pathogenesis of noncardia gastric cancer (4). A 
subgroup of H. pylori strains contains a gene associated with cytotoxin expression, namely 
CagA (cytotoxin-associated gene A). Compared to CagA negative strain, the CagA positive 
strain was deemed to further increase gastric cancer risk, through enhanced inflammatory 
responses (101). The association between H. pylori and pancreatic cancer has been addressed 
in a number of previous studies. Yet, the findings were largely inconsistent across studies. In 
a prior meta-analysis including four European studies (102), a pooled 56% excessive 
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pancreatic cancer risk was suggested, whereas an updated meta-analysis containing seven 
studies from Western countries could not substantiate the positive association (103). 
However, a strain-specific association between H. pylori (CagA+ or CagA-) and pancreatic 
cancer risk was indicated in a recent meta-analysis study (104).  
2.3.4 Chronic corpus atrophic gastritis 
Chronic corpus atrophic gastritis is identified as a precursor lesion of the intestinal type of 
noncardia gastric cancer (105), and it is characterized by a series of events during chronic 
gastric inflammation, including gland loss, mucosa thinning and epithelia cell regeneration 
and replacement (106). Autoimmune pernicious anemia, H. pylori infection and long-term 
treatment with proton pump inhibitors are identified as risk factors for chronic corpus 
atrophic gastritis (106-108). Hypergastrinemia and low serum pepsinogen levels have been 
characterized in chronic corpus atrophic gastritis. Practically, measurement of serum 
pepsinogens has been widely accepted for identification of presence of chronic atrophic 
gastritis in the general population, due to its economical and noninvasive features. We 
hypothesized that chronic corpus atrophic gastritis may be associated with an increased 
pancreatic cancer risk, through a mechanism of low-acid-production in the stomach.  
2.4 CURRENT HYPOTHESES FOR PATHOGENESIS  
2.4.1 Inflammation  
It is widely accepted that inflammation plays a key role in the development of pancreatic 
cancer (109-111). The link between local inflammation and pancreatic cancer comes from 
studies on the pancreatic carcinogenetic effects of chronic pancreatitis, which is a well-
established risk factor for pancreatic cancer (112-114). Other established risk factors, 
including smoking and obesity, may increase pancreatic cancer risk through promoting 
systemic inflammation (111). In addition, the microbiome appears to be linked to the cancer-
related inflammation and plays a pathogenic role in the process of inflammation. Several 
studies suggested that pathogenic infection is likely to convert the commensal bacterial 
population from a symbiotic state to a dysbiotic state, which will lead to the formation of 
systemic inflammation (115, 116). Inflammation is thought to play a key role in the etiology 
of pancreatic cancer, as it fosters a microenvironment that facilitates accumulation of genetic 
alterations and initiates carcinogenesis; the sustained microenvironment thus favors for 
pancreatic cancer development (110, 117). Further, tumor cells are developed to evade 
immune surveillance, including down-regulating the tumor-specific antigens or suppressing 
the antitumor immune cells, which results in immune evasion and escape (118, 119).  
2.4.2 N-nitrosamine compounds 
Studies in animal models during the past three decades have demonstrated that N-nitrosamine 
carcinogens are able to induce pancreatic cancer (120-123). N-nitrosamine compounds may 
reach the pancreas either through the duodenum or through the bloodstream. The ductal 
epithelium is able to metabolically activate the N-nitrosamine carcinogens (124). The 
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activated carcinogens may damage DNA by generating small DNA adducts or causing 
single-strand breaks (125). Long-term exposure of N-nitrosamine compounds overwhelms 
DNA repair capabilities, which exerts a pancreatic carcinogenesis effect. Usually, N-
nitrosamine is at extremely low level in the human environment. High levels of N-
nitrosamines are thought to be accumulated through tobacco products and dietary sources 
(120). 
2.4.3 Insulin resistance  
It has been hypothesized that exposure to a higher level of insulin, as well as insulin 
resistance, may increase the exocrine pancreatic cancer risk (126). Due to the anatomical 
proximity between exocrine cells and the islets of Langerhans, it has been estimated that the 
exocrine cells are exposed to insulin concentrations 20-fold higher than the systemic 
circulation, which may facilitate pancreatic cancer cell initiation, invasion and progression 
(127). Numerous studies in animal models and human cancer cell lines indicated that 
peripheral insulin resistance may exert a ductal pancreatic carcinogenesis effect (128-132) . 
In a recent epidemiologic study with five prospective US cohorts, the findings implied that 
peripheral insulin resistance, rather than hyperglycemia or pancreatic β-cell dysfunction, is 
independently related to an increased pancreatic cancer risk (133). 
2.4.4 Genetic susceptibility 
Both inherited high-penetrance mutations and low-penetrance loci increases pancreatic cancer 
risk. The high-penetrance mutations are characterized by familial aggregation (134, 135), and 
previous studies have identified several germline mutations in BRCA2, CDKN2A, STK11, 
APC, BRCA1, PRSS1, SPINK.  However these mutations account only for a small fraction of 
all pancreatic cancer cases (8-10%). On the other hand, multiple common susceptibility 
variants have been identified in genome-wide association studies (GWAS), and were reported 
to be associated with an altered pancreatic cancer risk (136-139), including 9q34.2 (ABO), 
13q22.1 (KLF5), 5p15.33 (TERT and CLPTM1), 13q12.2 (PDX1), 1q32.1 (NR5A2), 7q32.3 
(LINC-PINT), 16q23.1(BCAR1), 22q12.1 (ZNRF3), 17q25.1 (LINC00673) and 2p13.3 
(ETAA1). The identified susceptibility loci highlight the importance of the common variants 
in pancreatic cancer risk, and may provide deep insights in risk stratification, early detection 
and targeted treatment for this lethal cancer. Biological underpinnings of those common 
variants, as well as exploration of the interactions between these risk variants and 
environmental risk factors, await further follow-up studies.  
2.5 TUMOR MUTATIONS 
Pancreatic cancer is a heterogenetic disease, and accumulated genetic alterations play a key 
role in the pancreatic carcinogenesis, promoting the progression from a normal cell to 
precursor lesions and ultimately to invasive and metastatic carcinoma. Pancreatic cancer is 
characterized by a dominance of KRAS mutations, the majority being point mutations, and the 
minority either insertions or deletions. KRAS is the most commonly mutated oncogene in 
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PDAC (140, 141), and it encodes a small GTPase that regulates downstream signaling. 
Commonly, the hotspot mutation for KRAS is on codon 12, and less frequently mutations 
harbored on codon 13 and codon 61. In addition, three tumor suppressor genes, including 
TP53, CDKN2A, and SMAD4, are found to be recurrently mutated in PDAC. TP53 gene 
encodes a crucial component of the cellular stress response, and the mutation of TP53 usually 
causes diffusion of nuclear expression by TP53 protein, which can be detected by 
immunohistochemistry (142). CDKN2A gene encodes an important cell cycle regulator, and it 
is reported to be inactivated through several mechanisms, including intragenic mutation, 
homozygous deletion, as well as promoter methylation (143) . SMAD4 gene encodes a critical 
component in the transforming growth factor β signaling pathway. Somatic inactivation of 
SMAD4 is usually through homozygous deletion or intragenic mutation, and is found to be 
associated with worse prognosis and extensive metastasis (144).  
Recent advancements in technology of NGS have allowed comprehensive cancer genomic 
studies. In 2008, the mutational landscape of pancreatic adenocarcinoma was depicted by 
Jones et al. (140), including a range of molecular alterations in 63 genes that affect a core set 
of 12 cellular signaling pathways in most tumors. Later, Biankin et al. identified 16 genes of 
both known and novel mutations, according to exome sequencing on 99 early-stage PDACs 
(141). In a study to evaluate the clonal relationships among primary and metastatic cancer on 
the basis of genomic sequencing of seven tumors, the authors modelled and estimated that it 
requires an average of 11.7 years for the evolution from the initiation of pancreatic 
carcinogenesis until the birth of parental clone cell, and another 6.8 years from the birth of 
parental clone cell to the birth of cell with metastasis ability (145). The data provided novel 
insights into the genetic features of pancreatic cancer progression, and defined a broad time 
window for early detection when the disease is still in a curative stage.  
One characteristic of pancreatic cancer is the formation of abundant stroma, containing 
proliferating myofibroblasts. For pancreatic cancer, the stroma is not only a mechanical 
barrier, but also contributes to promoting the tumor initiation, progression, invasion and 
metastasis. This presents a major challenge for genomic sequencing in PDAC, due to the 
mixture of a large proportion of stromal cells with the tumor cells. The low malignant 
epithelial cell content largely limits the analytical performance of various sequencing 
methods in PDAC. Commonly, pancreatic tumor cells are transferred into an immortalized 
cell line in culture, yielding tumor cell population with high purity. Alternatively, the 
pancreatic tumor cells are transferred into xenografting mice to eliminate stromal cells. 
However, it is still an open question if additional genetic modifications may be produced in 
the creation of these immortalized cell lines or during the xenografting. Thus these samples 
may not be fully representative of the spectrum of heterogeneity of the original primary 
tumors. Further, it is also time-consuming and, importantly, not every tumor is able to 
generate a successful xenograft. Therefore, sensitive and accurate methods that can be 
directly applied to the low-tumor-cellularity samples are urgently warranted to identify the 
genetic aberrations in pancreatic tumors. 
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Genetic analysis may provide deep insights into the etiology of PDAC. It is also crucial for 
the development of novel therapies as it may help stratify patients with well-characterized 
molecular markers into subgroups which, in turn, can be used for development of 
personalized treatments targeting specific pathways. 
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3 AIMS 
The overarching aim of this thesis is to enrich our understanding of the etiology and 
epidemiology of pancreatic cancer.  
The specific aims are: 
• To explore the association between hepatitis C or hepatitis B virus infection and 
pancreatic cancer risk. 
• To determine whether poor oral hygiene is associated with a higher pancreatic cancer 
risk. 
• To evaluate the possible association between H. pylori infection and pancreatic cancer 
risk, as well as to examine whether presence of chronic corpus atrophic gastritis is 
related to an increased pancreatic cancer risk. 
• To explore molecular alterations of the selected candidate genes in PDAC, and to 
examine their associations with prognosis and environmental exposures. 
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4 MATERIALS AND METHODS 
4.1 STUDY MATERIALS 
4.1.1 Swedish data sources 
4.1.1.1 The Swedish Cancer Register 
The Swedish Cancer Register was launched in 1958 and is maintained by the National Board 
of Health and Welfare, using from the 7th edition of International Classification of Diseases 
(ICD-7) throughout. It is mandatory for health care providers, including physicians, 
pathologists and cytologists, to report newly diagnosed cancer cases from clinical, 
morphological and other laboratory examinations and autopsies. Staging information has 
been systematically included since 2004. The estimated overall completeness of the Swedish 
Cancer Register is high (>98%), but completeness rates may vary according to cancer sites 
(146, 147). Death certificate only cases are not included in the Swedish Cancer Register.  
4.1.1.2 The Swedish Causes of Death Register 
The Swedish Causes of Death Register is on the basis of death certificates, including 
information on the date of death, the underlying and contributory causes of death for all 
Swedish residents, with nationwide coverage since 1911. The causes of death are classified 
on the basis of ICD-7 (through 1968), ICD-8 (1969-1986), ICD-9 (1987-1996) and ICD-10 
(since 1997).    
4.1.1.3 The Swedish Inpatient Register 
The Swedish Inpatient Register was initiated by the Swedish National Board of Health and 
Welfare in 1964-1965. Its national coverage was 60% in 1969, 85% in 1983, and 100% in 
1987. The register contains information on the dates of admission and discharge and also 
diagnoses at discharge. The diagnoses were coded according to ICD-7 (through 1968), ICD-8 
(1969-1986), ICD-9 (1987-1996) and ICD-10 (since 1997). 
4.1.1.4 The Swedish HCV and HBV cohorts 
In Sweden, both the diagnosing laboratory and clinician are required to report diagnosed 
HCV and HBV infections to the SMI since 1990 and 1969, respectively. The notifications 
from various sources were merged in the national surveillance database through the use of 
Personal Identification Number. We established HCV and HBV cohorts based on the 
identified HCV and HBV infection notifications in the surveillance database in SMI from 
1990 to 2006 (148, 149).  
The HCV notifications from the diagnosing laboratory are based on a positive HCV-RNA or 
anti-HCV test, while HBV notifications are based on positive HBsAg or HBV-DNA. The 
reports from clinicians include further information, for example, probable route of 
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transmission and whether it is an acute or chronic infection of HBV. This is determined by 
clinical information and medical history.  
Exclusion criteria included multiple notifications, erroneous documentation, incomplete 
personal follow-up data, and those with acute HBV infection (N=2050), those with co-
infection that were reported to both the HCV and HBV register (N=3556). Overall, a total of 
39 442 patients with HCV infection and 11 511 patients with chronic HBV infection were 
enrolled. 
To identify an appropriate reference population, a quintuple larger reference population was 
generated from the Total Population Register at Statistics Sweden. The individuals in the 
reference population were those who had never been diagnosed with a HCV or HBV 
infection, and were randomly selected from the general population, five to one matched with 
HCV- or HBV-infected patients on year of birth, sex and county of residence in Sweden. In 
Study I, follow-up started on the entry date, either their HCV/HBV notification date or the 
assigned index entry date (non-infected reference population), until the date of first primary 
cancer diagnosis, emigration out of Sweden, death or December 31, 2008, whichever 
occurred first. 
4.1.1.5 The Swedish oral-mucosal-lesion cohort  
A population-based prevalence study of oral diseases was conducted in Uppsala county of 
Sweden from 1973 to 1974. At baseline, a professional clinical examination and 
questionnaire were offered to 30 118 individuals who were aged 15 or more and residing in 
this area. Overall, a total of 20 333 (10 036 men and 10 297 women) accepted to participate 
in the study. During the clinical examination, information such as number of teeth, dental 
plaque and oral mucosal lesions, were collected (150).  
A total of 121 persons were excluded during the cross-linkage due to the following reasons: 
individuals’ national registration numbers (NRN) were incorrect (N=84); individuals had 
changed NRNs during follow-up period (N=14); individuals had illegible data (N=8); 
individuals were inadvertently examined twice (omit data from the second examination; 
N=15), leaving a total of 20 212 eligible individuals. After linkage to the Cancer Register, 
288 individuals were further excluded given the reason that they had a cancer diagnosis 
before the entry date. In total, 19 924 participants were included in the study cohort for final 
analysis.  
In Study II, follow-up of the cohort members started from the date of dental examination 
(1973-74), and ended at the date of diagnosis of a first malignancy, death, emigration out of 
Sweden, or December 31, 2012, whichever occurred first.  
4.1.1.6 The Stockholm pancreatic cancer study 
This study was based on the incident cases of pancreatic cancer in the Stockholm county 
between 2007 and 2012. Criteria of the eligible cases were: younger than 85 years of age, 
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born in Sweden and living in the county of Stockholm. Through a network that consisted of 
all surgical clinics and the only oncological clinic in Stockholm county, the study was able to 
obtain a majority of newly diagnosed pancreatic cancer cases in Stockholm county in this 
period. When a pancreatic cancer case was diagnosed, the individual was asked whether 
he/she would like to take part in the study. After informed consent was obtained, the study 
coordinator at Karolinska University Hospital then informed Statistics Sweden professional 
interviewers to interview the case patient. The questionnaire addresses items on 
demographics, socioeconomic factors, physical activity, height, weight history, tobacco 
smoking, snuff use, dental health, earlier concomitant diseases, and medication history. A 
structured food frequency questionnaire was also included.  
Based on the Stockholm pancreatic cancer case-control study, the pancreatic cancer patients 
undergoing resection surgery from 2007 to 2012 were enrolled in this study. Fresh-frozen 
pancreatic cancer tissues from surgical resection (N=73) and matched peripheral blood 
samples (N=55) were obtained from Karolinska University Hospital. Through the NRNs, 
tumor characteristics and survival time of all participating patients were retrieved via the 
electronic patient record system at Karolinska University Hospital, which consists of detailed 
information on tumor stage, chemotherapy, date of surgery, and date of death. Data from the 
aforementioned interviews were available for 57 out of 73 PDAC patients.  
4.1.2 European data sources  
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a large 
prospective cohort study. From 1992 to 2000, the study recruited 519 978 participants who 
mostly aged between 35 to 70 years from 23 centers in 10 European countries (Denmark, 
France, Germany, Greece, Italy, the Netherlands, Spain, Norway, Sweden and the United 
Kingdom). A non-dietary questionnaire on lifestyle variables and a dietary questionnaire with 
detailed dietary items were collected at enrolment for all participants. Anthropometric 
measurements were conducted.  Blood samples were also taken, including plasma, serum, red 
cells and buffy coat fractions, which were separated and aliquoted for long term storage 
(151). Follow-up of EPIC study started from participants’ recruitment date to the date of 
cancer diagnosis, death, emigration, or December 31, 2006, whichever came first.  
We conducted a nested case-control study within the EPIC cohort study. With the incidence 
density sampling procedure, cancer-free control subjects were randomly selected and 
individually matched to each case patient on study center, age (± 3 years), sex, date (± 3 
months), time(± 2 h), and fasting status (<3 h, 3–6 h or >6 h ) at blood collection. To the end 
of 2006, 448 cases and 448 controls were enrolled and eligible in this study. 
4.2 IDENTIFICATION OF PANCREATIC CANCER  
For Study I and II, Pancreatic cancer was identified from the Cancer Register (ICD-7: 157) 
for the main analyses, and also from the Causes of Death Register (ICD-9: 157; ICD-10: 
C25) for additional analyses. 
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For Study III, incident pancreatic cancer cases were identified through population cancer 
registers in Denmark, Italy, the Netherlands, Norway, Spain, Sweden and the United 
Kingdom. In France, Germany and Greece, a combined approach was applied including 
linkage to health insurance records, cancer and pathology registers, and active follow-up of 
study participants and their next-of-kin. A total of 578 primary incident pancreatic cancer 
cases were identified using International Classification of Diseases, 10th Revision codes 
(ICD-10, C25.0-25.3, 25.7-25.9) by the end of 2006. Given the different etiology and 
pathogenesis, endocrine pancreatic tumor cases (ICD -O-3 C25.4, histologic type and 
morphology codes 8150, 8151, 8153, 8155, 8240 and 8246) were excluded from the study. 
Further, cases without blood samples were excluded, leaving a total of 448 eligible pancreatic 
cancer cases. 
For Study IV, PDAC patients were ascertained within the framework of the clinical 
healthcare system of the Stockholm County.  
4.3 LABORATORY METHOD 
4.3.1 Commercially available test: Enzyme linked immunosorbent assays (ELISAs) 
(Study III) 
4.3.1.1 H. pylori serostatus 
We measured serum concentration of antibodies against whole H. pylori antigens using a 
commercial H. pylori IgG ELISA kit (Biohit, Helsinki, Finland). The enzyme immunounits 
(EIU) were determined as following: sample EIU = [mean optical density (OD) value of 
sample – mean OD value of blank]/[ mean OD value of calibrator – mean OD value of 
blank]*100. The cutoff point was a value of 30 EIU; equal or more than this value was 
defined as H. pylori seropositive.  
4.3.1.2 CagA serostatus 
The serum concentration of antibodies against CagA was measured by a commercial 
Helicobacter pylori p120 (CagA) IgG ELISA kit (Ravo Diagnostika GmbH, Freiburg, 
Germany). The EIU were calculated based on the formula as following: sample EIU = [mean 
optical density (OD) value of sample – mean OD value of blank]/[ mean OD value of 
calibrator – mean OD value of blank]*unit value of calibrator. CagA seropositive was 
determined by a value of 7.5 EIU or more.  
4.3.1.3 Pepsinogen I and pepsinogen II levels 
Serum levels of pepsinogen I and II were measured by pepsinogen I and pepsinogen II 
ELISA kits (Biohit, Helsinki, Finland), respectively. Calibration curves were produced to test 
the serum concentrations of PGI or PGII. A serum concentration of PGI < 25 µg/l or PGI/ 
PGII < 3 was considered as presence of chronic corpus atrophic gastritis, with sensitivity and 
specificity of 71% (CI 68-74%) and 98% (CI 97-99%), respectively (152). 
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4.3.1.4 Quality control 
The laboratory staff was blinded regarding case/control status. In each plate for the tested 
samples, control samples were added and designed to monitor the test quality, including a 
positive control sample, a blank sample and a negative control sample that were provided by 
the producer, and two internal control samples (generated by pooling the sera donated by 5 
healthy volunteers). The titer values yielded from the control samples provided by the 
producer to control the within-assay imprecision were all within the expected ranges. 
Coefficients of variation, generated from values of the internal controls to control the 
between-assay imprecision, were 9.7% for H. pylori, 10.3% for CagA, 5.0% for PGI, and 
7.9% for PGII, respectively.  
4.3.2 Anchored Multiplex PCR (AMP)-based method (Study IV) 
4.3.2.1 Custom target design 
A panel of 65 clinically related cancer genes, including a 39-gene sub-panel of genes with 
recurrent mutations in solid tumors (from COSMIC database), and an exploratory sub-panel 
of 26 genes (from the Global Pancreatic Genomic study), was targeted for sequencing. The 
full coding regions were selected for the tumor suppressor genes, and selected exons for 
oncogenes.  
4.3.2.2 DNA extraction and construction of sequencing libraries 
Extraction of genomic DNA was carried out using the QIAamp DNA Mini Kit (Qiagen, 
Valencia, CA, USA). DNA libraries were prepared according to the AMP-based method 
(153). In brief, 200 ng genomic DNA was sheared to a mean size of 500 bp on a Covaris 
S220 instrument (Covaris, Woburn, MA, USA). Sheared fragments were processed with end 
repair (End-Repair Mix, Enzymatics, MA, USA), adenylation (Klenow Exo-, Enzymatics; 
Taq Polymerase, Life Technologies), and ligation (T4 DNA Ligase, Enzymatics). Illumina 
MiSeq adapters have been incorporated with a molecular index for tracking purpose. The 
ligated products were further cleaned by solid phase reversible immobilization, and then two 
rounds of nested polymerase chain reaction (PCR) were run for targeted enrichment 
(Platinum Taq Polymerase, Life Technologies), producing sequencing-ready libraries. 
Quantitation of the libraries was performed by quantitative PCR (Kapa Biosystems, Woburn, 
MA, USA) and sequenced on a MiSeq (Illumina, San Diego, CA). Thirty-two samples were 
pooled and sequenced in each MiSeq run.  
4.3.2.3 Validation of AMP-based method 
A quantitative multiplex DNA reference standard 
We sequenced a commercial quantitative multiplex DNA reference standard (Horizon 
Diagnostics, DNA HD701) to assess the analytical performance of the AMP-based method. 
The DNA reference standard contains 6 genes and 11 mutations (BRAF, KIT, EGFR, NRAS, 
KRAS, and PIK3CA) (52). The 11 mutations were all covered by the above-mentioned 39-
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gene sub-panel. During data analysis, EGFR G719S had the highest allele frequency, and 
served as an internal normalization reference, and was used to adjust the actual dilution ratios 
and to measure expected allele frequencies for all mutations in the same spike-in sample.  
Sanger sequencing 
Sanger sequencing was performed to evaluate mutations in KRAS (codons 12 and 13) that 
were identified by the AMP-based assay. An ABI 3730XL (PE Applied Biosystems, Foster 
City, CA, USA) was used for sequencing the purified PCR products, and data were analyzed 
by Chromas Version 2.4. 
Allele-specific PCR 
Allele-specific PCR was applied to validate mutations in KRAS codon 12 with allelic 
fractions too low (<5%) to be confirmed by the Sanger platform. A few samples with higher 
mutant allelic fractions were randomly selected and served as positive controls for allele-
specific PCR. The 3’ terminal base of the allele-specific primer (G12D, G12R or G12V) was 
designed to be identical to its corresponding mutation. Exonuclease I/SAP (New England 
BioLabs) was applied to the PCR products to remove unincorporated primers. Agarose gel 
electrophoresis (1%) was performed to identify the target amplicons.  
Digital PCR 
Digital PCR was performed to validate low-level KRAS mutations at codon 12 (<5%). KRAS 
G12D, G12V, and G12R mutations were measured separately using TaqMan SNP 
Genotyping Assays optimized for digital PCR on a QuantStudio 3D Digital PCR System 
(Life Technologies).  
4.4 STATISTICAL ANALYSES 
In study I, the R language for statistical computing (R Core Team, 2011) was used for all 
statistical analyses. In study II to IV, all statistical analyses were performed using the 
Statistical Analysis System (SAS) software package, version 9.3 (SAS Institute, Cary, NC). 
All statistical tests were two-sided and statistical significant level was set at the 5% level.  
4.4.1 Standardized incidence ratio (Study I) 
In Study I, the standardized incidence ratio (SIR) was measured as the ratio of the observed 
number of pancreatic cancer cases in the HCV or HBV cohort to the expected case number 
from the general population. In each cohort, to calculate the expected numbers, the observed 
person-time in each 5-year age group by sex and the corresponding Swedish population 
incidence rates were used. 95% confidence intervals (CIs) were calculated based on the Max 
method (154).  
Stratification analyses were performed by sex, infection duration, and year of birth 
(before/after 1960).  
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4.4.2 Cox proportional hazards regression model (Study I, II) 
In Study I and II, the associations between exposure variables and risk of pancreatic cancer 
were examined by hazard ratios (HRs) and the corresponding 95% CIs derived from Cox 
proportional hazards regression models. For Study I, due to matching by birth year, sex and 
county of residence, these factors were inherently adjusted in the model. Potential 
confounding factors were further adjusted in the Cox model, including hospitalizations for 
chronic obstructive pulmonary disease, diabetes mellitus, chronic pancreatitis and alcohol 
abuse. Because acute pancreatitis might be a complication to interferon therapy for HCV 
infection, and pancreatitis is a risk factor for pancreatic cancer. We further performed 
additional analysis that excluded all HCV infected patients who were ever hospitalized for 
acute and/or chronic pancreatitis. 
In assessing poor oral hygiene as a risk factor for pancreatic cancer (Study III), the models 
were adjusted for age (as time scale), sex and attained calendar period in 10-year-intervals 
(1973-1982, 1983-1992, 1993-2002 and 2003-2012). For potential confounding factors, we 
further adjusted for tobacco use (non-tobacco user, pure smoker, pure snus user or mixed type 
user), alcohol consumption (low vs moderate or high), and area of residence (rural, small 
municipality or town). Stratification analysis was performed by sex.  We also assessed the 
interaction between poor oral hygiene and sex by including a multiplicative interaction term 
into the model. In addition, to assess any influence of reverse causation, we performed a 
sensitivity analysis that excluded the first 2 years of follow-up.  
4.4.3 Logistic regression model (Study III, IV) 
In Study III, conditional logistic regression models were applied to calculate the odds ratios 
(ORs) and 95% CIs for the association between exposure variables and pancreatic cancer.  
The aforementioned matching factors were inherently adjusted in the models. In addition, 
potential confounding factors were further adjusted in the models, including smoking status 
(never, former or current), diabetes mellitus status (no or yes), height and waist-to-hip ratio. 
To estimate stratum-specific effects by blood group, a 4-category new variable was created 
by combining two dichotomous variables, e.g. H. pylori/CagA seropositivity (H. pylori 
negative and CagA negative vs H. pylori positive or CagA positive) and blood group (O vs 
non-O); dummy variables were then generated and introduced into regression models. To 
examine whether the association between H. pylori and/or CagA serostatus and pancreatic 
cancer was significantly modified by ABO blood group (O vs non-O blood type), an 
interaction term was introduced into the regression model and p value for the interaction term 
was derived from a Wald test. Similarly, the stratum-specific effects of chronic corpus 
atrophic gastritis by H. pylori/CagA serostatus were examined, and the interaction between 
these two variables was tested. To allay the concern that socioeconomic status (SES) may be 
a potential confounding factor for the association between H. pylori and pancreatic cancer, 
we further performed a sensitivity analysis by additionally including SES in the models. To 
minimize the influence of reverse causation bias, sensitivity analysis was performed by 
excluding the first 2 years of follow-up. To eliminate the non-fasting plasma effect, we 
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further conducted a sensitivity analysis by excluding case-control pairs with the fasting status 
of less than six hours since their last meal to blood collection.  
In Study IV, logistic regression model was used to examine the association between tobacco 
smoking and overall genetic transversion or transition rate, adjusted for sex and age at entry.  
4.4.4 Survival analysis (Study IV) 
In Study IV, survival analysis was conducted among patients of PDAC with stage T3 tumors 
without distant metastasis. Follow-up of patients started from the date of surgery and was 
censored at death or January 1, 2014, whichever occurred first. The Kaplan-Meier method 
was used to estimate survival curves stratified by KRAS mutation subtype, mutation status 
(yes/no) in TP53 and transforming growth factor β (TGFB) signaling pathway genes (SMAD4 
or TGFBR2).  Log-rank test was applied to compare survival curves. 
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5 RESULTS 
5.1 HCV OR HBV INFECTION AND PANCREATIC CANCER RISK (STUDY I) 
Baseline characteristics of the HCV and HBV cohorts are shown in Table 1. The mean 
follow-up time was 9.1 and 9.4 years in the HCV and chronic HBV cohorts, with a total of 
360 154 and 107 986 person-years at risk, respectively. The HCV cohort had a greater 
proportion of males, and individuals in this cohort were more likely from Nordic countries. 
However, chronic HBV-infected individuals tended to be immigrants from non-Nordic 
countries.  
Table 1 Characteristics of the chronic hepatitis C virus (HCV) infection and the hepatitis B virus 
(HBV) infection cohorts, 1990-2006 
 
 HCV cohort 
N=39 442 (%) 
Chronic HBV cohort  
N=11 511 (%) 
Deceased  7872 (20.0) 738 (6.4) 
Emigrated 1326 (3.4) 780 (6.8) 
Person-years accumulated 
during follow-up 
360 154  107 986 
Mean follow-up time, years 9.1 9.4 
Male sex % 27 024 (68.5) 6117 (53.1) 
Median age at HBV/HCV 
notification  
(males, females) 
38 (38, 37) 31 (33, 29) 
Year of birth, median (range) 1958 (1898, 2006) 1967 (1906, 2006) 
Country of origin   
Nordic countries 35 033 (88.8) 1779 (15.5) 
Non-Nordic  European countries 2035 (5.2) 3166 (27.5) 
Other 2305 (5.8) 6482 (56.3) 
Suspected route of virus 
transmission 
  
Intravenous drug use 21 941 (55.6) 178 (1.5) 
Blood/blood products 2423 (6.1) 179 (1.6) 
Sexual contact 891 (2.3) 334 (2.9) 
Nosocomial transmission 130 (0.3) 38 (0.3) 
Mother-child 92 (0.2) 762 (6.6) 
Other 848 (2.1) 2744 (23.8) 
Unknown or missing 13 117 (33.3) 7276 (63.2) 
 
In the HCV cohort, we identified 34 pancreatic cancer cases and 16.5 were expected during 
340 819 person-years of follow-up (first 6 months of follow-up were excluded), rendering a 
two-fold increased risk of pancreatic cancer. The SIRs did not vary notably across sex or 
estimated duration of HCV infection, but a stronger association was found among patients 
born after 1960 (Table 2). In the Cox regression model, HCV infected individuals had a 90% 
excess risk of pancreatic cancer after adjustment of age, sex and county of residence, which is 
consistent with the result from the SIR analysis. Additional adjustment for potential 
confounders diminished the strength of association somewhat, but the excess risk still 
remained statistically significant (Table 3). In the sensitivity analysis, after excluding 
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individuals ever hospitalized for pancreatitis (acute/chronic), the results did not change 
substantially (data not shown).  
Table 2 Standardized incidence ratio (SIR) for pancreatic cancer among 39 442 individuals infected 
with hepatitis C virus (HCV) compared with the general population 
 Pancreatic cancer 
 Oa Eb SIR (95%CI) 
Lag period after HCV-notification   
≤ 6 months 4 0.8 5.3 (1.4, 13.5) 
> 6 months 34 16.5 2.1 (1.4, 2.9) 
Sexc    
Men 23 11.5 2.0 (1.3, 3.0) 
Women  11 5.0 2.2 (1.1, 3.9) 
HCV-durationc, d    
 ≤ 20 years 10 5.4 1.9 (0.9, 3.4) 
> 20 years 24 11.1 2.2 (1.4, 3.2) 
Year of birthc    
before 1960 31 15.5 2.0 (1.4, 2.8) 
from 1960 3 1.0 3.0 (0.6, 8.8) 
aObserved number of pancreatic cancer cases. 
bExpected number of pancreatic cancer cases. 
cExcluding cases and observation-time during the first 6 months after HCV notification. 
dEstimated duration of HCV-infection. 
 
In the HBV cohort, we found a 40% increased pancreatic cancer risk in the SIR analysis, but 
without statistical significance (data not shown). In the Cox regression model, the point 
estimate was somewhat higher (HR=2.0 after adjustment for only matching factors and 
HR=1.8 after full adjustment), but still did not reach the statistical significant level (Table 3). 
Table 3 Hazard ratios of pancreatic cancer associated with hepatitis C virus (HCV) infectiona, and 
with chronic hepatitis B virus (HBV) infectiona 
  
 Pancreatic cancer 
 Cases  HR (95% CI) 
Total 154  
Non-HCV infection 120 1.0 
HCV-infectionb 34 1.9 (1.3, 2.7) 
HCV-infectionc 34 1.6 (1.04, 2.4) 
   
Total 21  
Non-HBV infection 16 1.00 
HBV-infectionb 5 2.0 (0.7, 5.3) 
HBV-infectionc 5 1.8 (0.7, 5.1) 
aFirst 6 months of follow-up after HCV or HBV notification were excluded. 
bInherently adjusted for birth year, sex and county of residence in the model. 
cAdjusted additionally for chronic obstructive pulmonary disease, diabetes mellitus, chronic 
pancreatitis and alcohol-related diseases.  
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5.2 POOR ORAL HYGIENE AND PANCREATIC CANCER RISK (STUDY II) 
In this study, participants with fewer teeth at baseline appeared to be older, female and had 
a shorter follow-up duration. Similarly, cohort members with more dental plaque were 
older, male, and had a shorter follow-up duration. They were also more likely to be a 
smoker or snus users and consumed more alcohol, compared to individuals who had no 
dental plaque.  
Table 4 demonstrates HRs for pancreatic cancer associated with different indicators of poor 
oral hygiene. Subjects with fewer teeth at baseline, compared to subjects with more teeth at 
baseline, appeared to have an increased pancreatic cancer risk, but the HR estimates were 
not statistically significant. On the other hand, when we used presence of dental plaque as 
an indicator for poor oral hygiene, we found that subjects with an unacceptable dental 
plaque status had a doubled risk of pancreatic cancer. As for oral mucosal lesions, the HRs 
were 1.7 and 1.3 for individuals with Candida- related oral mucosal lesions and denture-
related oral mucosal lesions, respectively, which were of borderline statistical significance. 
Furthermore, individuals with tongue lesions had a statistically significant 80% increased 
risk for pancreatic cancer. Presence of more than one type of oral mucosal lesions further 
elevated the risk of pancreatic cancer. The highest HR of pancreatic cancer was observed 
among the individuals with all the three studied oral mucosal lesions (HR=3.1, 95% CI: 1.3, 
7.6) (Table 4).  
Additional adjustment for confounding factors had a negligible effect on the relative risk 
estimates (Table 4). Analysis stratified by sex indicated no heterogeneity for the 
associations (data not shown). We further restricted the analysis by excluding the first 2 
years of follow-up, and the results did not alter significantly (data not shown).   
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Table 4 Hazard ratios (HRs) for pancreatic cancer according to number of teeth, dental plaque and oral mucosal lesions in a cohort study from 1973 to 2012.a 
Characteristics Total 
number (N) 
Cases  (N) Person-years IR (per 100,000 
person-years)b 
Crude HR (95% 
CI)c 
Multivariable-
adjusted HR 
(95% CI)d 
Number of teeth at baselinee       
21-32 9490 30 331 884 14.7 1.0 1.0 
11-20 5918 51 159 886 22.4 1.3 (0.8, 2.1) 1.2 (0.7, 2.0) 
0-10 4516 45 80 360 30.1 1.4 (0.8, 2.5) 1.3 (0.7, 2.3) 
Ptrend     0.27 0.38 
Dental plaquef       
No  3203 10 105 270 12.1 1.0 1.0 
Acceptable  9581 52 313 205 21.2 1.8 (0.9, 3.5) 1.8 (0.9, 3.6) 
Unacceptable  2624 19 73 295 27.5 2.1 (1.0, 4.6) 2.1 (1.0, 4.7) 
Ptrend     0.07 0.07 
       
Oral mucosal lesions        
Reference  14 121 68 440 910 18.6 1.0 1.0 
Candida-related oral mucosal 
lesions (A)g 
1158 12 24 519 38.9 1.7 (0.9, 3.2) 1.7 (0.9, 3.3) 
Denture-related oral mucosal 
lesions (B)h 
4185 44 86 680 28.7 1.3 (0.9, 2.0) 1.3 (0.9, 2.0) 
Tongue lesions (C)i 2117 24 51 645 34.5 1.8 (1.1, 2.9) 1.8 (1.1, 2.9) 
Presence of both A and B 648 8 10 773 74.3* 1.8 (0.8, 3.9) 1.8 (0.8, 4.0) 
Presence of both B and C 708 11 12 682 63.2 2.1 (1.1, 4.2) 2.2 (1.1, 4.3) 
Presence of both A and C 603 9 12 825 70.2* 2.7 (1.3, 5.4) 2.6 (1.3, 5.4) 
Presence of all 3 lesions 302 6 4656 128.9* 3.1 (1.3, 7.6) 3.2 (1.3, 7.8) 
aHR=Hazard ratio; CI=confidence interval. 
bIR=incidence rate per 100 000 person-years, standardized to age distribution of person-years experienced by all participants using 5-year age categories. * Crude 
incidence rate per 100 000 person-years was presented, as age-standardized incidence rate might be misleading when the number of cases was small.  
cModels were adjusted for age (as time scale), sex and attained calendar period in 10-year-intervals (1973-1982, 1983-1992, 1993-2002 and 2003-2012).   
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dModels were adjusted for age (as time scale), sex and attained calendar period in 10-year-intervals (1973-1982, 1983-1992, 1993-2002 and 2003-2012), tobacco use 
(non-tobacco user, pure smoker, pure snus user or mixed type user), alcohol consumption (low vs high), and area of residence (rural, small municipality or town). 
eThe number of teeth calculation was based on presence or absence of 6 different teeth at baseline (tooth #16, #21, #24, #36, #41, #44); presence of 0-1, 2-5, 6 of the 
selected teeth examined was assumed to correlate to 0-10, 11-20 or 21-32 remaining teeth. 
fDental plaque calculation was based on six selected teeth on average, cut off criteria: No dental plaque (No dental plaque present); acceptable (dental plaque 
covering not more than one third of the tooth surface); unacceptable (dental plaque covering more than one third of the tooth surface). Dental plaque analyses were 
restricted to individuals with more than 10 teeth. 
gCandida-related oral mucosal lesions include pseudomembranous candidiasis, chronic candidosis, angular cheilitis, atrophic and nodular leukoplakia, median type 
of atrophy of tongue papillae and unspecified glossitis. 
hDenture-related oral mucosal lesions include denture stomatitis (localized, generalized and papillomatous), denture hyperplasia, traumatic ulcer and flabby ridges. 
iTongue lesions include lingua fissurata, and plicated tongue, atrophy of tongue papillae, hairy tongue, coated tongue, median rhomboid glossitis, and unspecific 
glossitis. 
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5.3 HELICOBACTER PYLORI INFECTION AND PANCREATIC CANCER RISK 
(STUDY III) 
At baseline of recruitment, the mean age of the cases and control subjects were 57.8 years. 
Cases, compared to control subjects, were more likely to be current smokers and appeared 
to have a history of diabetes. In general, the prevalence of H. pylori seropositivity, CagA 
seropositivity and serologically-defined presence of chronic corpus atrophic gastritis did 
not differ significantly between cases and controls. 
Our results illustrated that neither H. pylori seropositivity nor CagA seropositivity was 
associated with pancreatic cancer risk. Additional adjustment for confounding factors in the 
models did not alter the results appreciably (Table 5). Analysis stratified by smoking did 
not show significant heterogeneity of associations (p value for interaction = 0.11, fully-
adjusted model) (data not shown).  
In the combined analysis of H. pylori and CagA serostatus, the ORs were close to unity for 
subjects seropositive for H. pylori or CagA when compared with those seronegative for 
both H. pylori and CagA, and the null association remained unchanged across subgroups 
with different combinations of H. pylori and CagA serostatus (Table 5). In the sub-analysis 
among individuals with complete ABO blood type information (N=278 case-control pairs), 
a combined analysis of H. pylori/CagA serostatus and ABO blood type was performed. We 
did not find any excessive risk of pancreatic cancer in association with H. pylori/CagA 
seropositivity, in either O or non-O blood group (Table 5).  
On the other hand, the point estimates of OR indicated a slightly increased pancreatic 
cancer risk among individuals with presence of chronic corpus atrophic gastritis, although it 
did not reach a statistically significant level (Table 6). In order to address the possible 
modification effect of H. pylori infection on the association between chronic corpus 
atrophic gastritis and pancreatic cancer risk, stratified analysis was performed by H. pylori 
serostatus and a stronger association was observed in the stratum seronegative for both H. 
pylori and CagA (OR=5.66, p value for interaction < 0.01, fully-adjusted model) (Table 6). 
Sensitivity analyses by additionally adjusting for SES or excluding case-control pairs with 
less than 2 years of follow-up, revealed largely unchanged results. When we restricted the 
analysis to case-control pairs with fasting status of more than six hours since the last meal, 
the results remained essentially similar (data not shown).  
 
 
 
 
 
 
  27 
Table 5 Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for pancreatic cancer risk according to H. pylori serology: a case-
control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort 
 Control subjects Case patients Crude model1  Adjusted model2 
 N, % N, % OR (95% CI) OR (95% CI) 
H. pylori serology     
Negative 241 (53.9) 250 (56.0) 1.00  1.00  
Positive  206 (46.1) 196 (44.0) 0.91 (0.68, 1.21) 0.96 (0.70, 1.31) 
     
CagA serology     
Negative 306 (68.9) 302 (68.3) 1.00  1.00  
Positive  138 (31.1) 140 (31.7) 1.02 (0.76, 1.38) 1.07 (0.77, 1.48) 
     
H. pylori and CagA serology     
H. pylori-, CagA- 214 (48.3) 218 (49.5) 1.00  1.00  
H. pylori+ or CagA+ 231 (51.9) 224 (50.7) 0.94 (0.70, 1.25) 0.99 (0.73, 1.35) 
    H. pylori-, CagA+  25 (5.6) 28 (6.4) 1.11 (0.61, 2.02) 1.14 (0.59, 2.22) 
    H. pylori+, CagA- 91 (20.5) 82 (18.6) 0.88 (0.61, 1.27) 0.94 (0.63, 1.38) 
    H. pylori+, CagA+ 113 (25.5) 112 (25.4) 0.96 (0.68, 1.37) 1.04 (0.63, 1.38) 
     
Sub-analysis:  stratified by ABO blood group (N=278, case-control pair) 
O blood group 
H. pylori-, CagA-  59 (21.2) 49 (17.6) 1.00  1.00  
H. pylori+ or CagA+ 52 (18.7) 45 (16.2) 1.06 (0.57, 1.96) 1.17 (0.60, 2.30) 
Non-O blood type     
H. pylori-, CagA-,   76 (27.3) 86 (30.9) 1.00  1.00  
H. pylori+ or CagA+ 91 (32.7) 98 (35.3) 0.94 (0.60, 1.46) 0.86 (0.54, 1.38) 
1Crude conditional logistic regression model was inherently adjusted for the matching factors, including study center, sex, age at blood collection (±3 
years), date of blood donation (±3 months), time of blood donation (±2 h), and fasting status (<3h, 3-6h or >6 after the last meal). 
2Adjusted conditional logistic regression model was inherently controlled for the matching factors, and was further adjusted for height, waist-to-hip 
ratio, smoking status (never, former or current) and diabetes mellitus status (no or yes). 
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Table 6 Association between serologically-determined presence of chronic corpus atrophic gastritis and risk of pancreatic cancer: a case-control study 
nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort 
 Control subjects Cases Crude model1  Adjusted model2 
 N, % N, % OR (95% CI) OR (95% CI) 
Chronic corpus atrophic gastritis3     
No 415 (94.1) 407 (92.1)  1.00  1.00  
Yes 26 (5.9) 35 (7.9) 1.39 (0.81, 2.38) 1.35 (0.77, 2.37) 
     
Stratifying by H. pylori and CagA 
serostatus  
    
H. pylori+ or CagA+      
Chronic corpus atrophic gastritis (no) 204 (46.5) 202 (46.1) 1.00  1.00  
Chronic corpus atrophic gastritis (yes) 22 (5.0) 18 (4.1) 0.88 (0.45, 1.72) 0.85 (0.42, 1.72) 
H. pylori- and CagA-      
Chronic corpus atrophic gastritis (no) 210 (47.8) 202 (46.1) 1.00  1.00  
Chronic corpus atrophic gastritis (yes) 3 (0.7) 16 (3.7) 5.29 (1.53, 18.23) 5.66 (1.59, 20.19) 
1Crude conditional logistic regression model was inherently adjusted for the matching factors, including study center, sex, age at blood collection (±3 
years), date of blood donation (±3 months), time of blood donation (±2 h), and fasting status (<3h, 3-6h or >6 after the last meal). 
2Adjusted conditional logistic regression model was inherently controlled for the matching factors, and was further adjusted for height, waist-to-hip 
ratio, smoking status (never, former or current) and diabetes mellitus status (no or yes). 
3Presence of chronic corpus atrophic gastritis was defined as pepsinogen I <25 μl/l or pepsinogen I/II <3.  
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5.4 VARIANT PROFILING OF PANCREATIC CANCER (STUDY IV) 
The average age of the patients at surgery was 68.2 years, and 53.4% were men.T3 was the 
predominant tumor stage (80.8% of cases). Among the 57 patients with available smoking 
information, the majority were ever-smokers (75.4%).  
5.4.1 Validation of the AMP-based assay by sequencing a quantitative multiplex DNA 
reference standard 
To evaluate the analytical performance of the AMP-based assay, nine spike-in samples of 
the reference DNA (at three dilution ratios, performed in triplicate) were sequenced in one 
MiSeq run. Except for one sample due to poor performance, a minimum of 250X de-
duplicated (molecular index consolidated) sequencing coverage was obtained for more than 
90% of target regions for the rest.  
Expected allele frequencies with ranges from 6.30% to 18.38% were successfully detected 
by the AMP-based assay (31 variants). For the 49 variants with allele frequencies ranging 
from 1% to 5%, 44 variants were detected and five variants were rejected (one variant: 
2.63% allele frequency and 336X depth; four variants ≤ 158X depth). Nine out of 19 
variants with the very low allele frequency (0.16% to 0.96%) were detected. Figure 1 
reveals that to detect variants with allele frequency of 2.5%, sequencing depth greater than 
~1000X was needed, and for a frequency of 1%, ~1500X depth was needed.  
 
 
Figure 1 Detectable variant allelic frequencies according to sequencing depth, anchored multiplex 
PCR (AMP)-based assay.  
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5.4.2 Frequency and distribution of genetic aberrations 
We identified a total of 95 non-synonymous variants, seven synonymous variants, and five 
insertions or deletions by using the AMP-based method in the 73 PDACs. Figure 2 depicts 
variants in 13 genes identified in at least one patient. Eighty-four percent of PDACs 
harbored at least one variant in the targeted regions.  
 Figure 2 Concurrent and mutual exclusion of non-synonymous variants and frameshift indels 
observed across genes in pancreatic ductal adenocarcinoma. Tumors with and without alterations in 
the genes are labeled in green and grey, respectively, in the corresponding columns. Sex, T stage 
(according to TNM classification), and tobacco smoking status are also indicated. 
The prevalence of KRAS was 78%, and 33% of the samples were of low-mutant-allelic-
frequency (< 15%), and 8% of the samples were of very-low-mutant-allelic-frequency 
(<5%). The most prevalent KRAS mutations were G12D (GGT>GAT), G12R (GGT>CGT), 
and G12V (GGT>GTT). A total of 59 samples, with high mutant frequencies (> 5%) or 
without detectable mutations in KRAS on codons 12 and 13, were completely validated and 
confirmed by Sanger sequencing. The remaining low-mutant-allelic-frequency samples (< 
5%, N=14, two samples harboring KRAS Q61H mutation are not shown in Table 7) 
detected by the AMP-based method were out of the detection limit for conventional Sanger 
sequencing. Mutations in these low-mutant-allelic-frequency samples were further 
confirmed by allele-specific PCR and digital PCR. The validation study demonstrated that 
the results from AMP-based assay were completely consistent with those from the Sanger 
sequencing (high-allelic-frequency samples), and were also fully consistent with those from 
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allele-specific PCR and digital PCR assays (low-allelic-frequency samples) (Table 7, 
Figure 3-6). 
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  Table 7 Low and high allele frequencies of KRAS codon 12/13 mutations detected by anchored multiplex PCR (AMP)-based next-generation sequencing, Sanger 
sequencing, allele specific PCR and digital PCR assays. 
Sample ID AMP-based NGS 
assay 
Mutant allele 
percentage by 
AMP-based 
NGS assay 
Sanger sequencing 
assay 
Allele specific 
PCR assay 
Digital PCR assay 
Relative quantification  
(95% confidence 
interval), %  
Absolute quantification 
(95% confidence interval), 
copies/μL 
Sample 30 p.G12D 1.14 Negative  p.G12D 2.13 (1.68 - 2.67) 5.12 (4.36 - 6.02) 
Sample 65 p.G12V 1.31 Negative  p.G12V 1.17 (1.18 - 1.98) 3.98 (3.33 -- 4.75) 
Sample 39 p.G12D 1.38 Negative  p.G12D 0.81 (0.59 - 1.11) 2.78 (2.23 - 3.46) 
Sample 64 p.G12D 1.80 Negative  p.G12D 1.86 (1.43 - 2.42) 3.88 (3.23 - 4.66) 
Sample 14 p.G12V 2.16 Negative  p.G12V 3.42 (2.68 – 4-37) 6.68 (5.70 -- 7.84) 
Sample 12 p.G12V 2.52 Negative  p.G12V 2.06 (1.61 - 2.63) 4.36 (3.44 - 5.54) 
Sample 26 p.G12R 2.52 Negative  p.G12R 2.49 (1.97 - 3.15) 4.65 (3.96 - 5.46) 
Sample 74 p.G12V 2.62 Negative  p.G12V 5.64 (4.95 - 6.43) 16.46 (15.10 -- 17.94) 
Sample 23 p.G12D 2.83 p.G12D p.G12D 3.88 (3.22 - 4.67) 10.29 (9.08 – 11.66) 
Sample 86 p.G12V 3.04 Negative  p.G12V 2.97 (2.40 – 3.67) 5.97 (5.16 - 6.90) 
Sample 34 p.G12D 3.10 Negative  p.G12D 1.79 (1.43 - 2.22) 5.80 (4.99 – 6.75) 
Sample 55 p.G12D 3.36 Negative  p.G12D 2.14 (1.75 - 2.61) 7.15 (6.24 -- 8.20) 
Sample 43 p.G12V 7.76 Negative p.G12V 6.37 (5.20 – 7.83) 13.14 (11.51 - 15.01) 
Sample 44 p.G12R 30.34 p.G12R p.G12R 32.28 (29.99 - 34.71) 72.60 (69.64 - 75.68) 
Sample 45 p.G12V 41.45 p.G12V p.G12V 46.80 (43.97 - 49.75) 161.73 (156.74 -- 166.87) 
Sample 47 p.G12D 63.75 p.G12D p.G12D 65.81 (62.88 - 68.80) 422.26 (414.32 - 430.35) 
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Figure 3 Identification of mutations by anchored multiplex PCR (AMP)-based next-generation 
sequencing, visualized using the Integrative Genomic Viewer (top panel), and confirmed by Sanger 
sequencing (bottom panel). (A) KRAS G12D mutation. (B) KRAS G12R mutation. (C) KRAS G12V 
mutation. (D) KRAS wild-type. 
TP53 mutations ranked as the second most common alterations in PDAC, and were found 
in 25% of the samples. Of these, 6 and 7 of 18 were coexistent with KRAS G12D and G12R 
mutation, respectively. SMAD4 mutations were identified in 8.2% of PDACs, and 5.5% of 
the mutations coexisted with KRAS G12R mutation. GNAS mutations were harbored in 
4.1% of PDACs, and all GNAS mutations were concurrent with KRAS G12D mutation. The 
targeted genes with less frequent variants and the corresponding patients’ 
clinicopathological features are shown in Figure 2. The allele frequencies of the rare 
variants ranged from 0.21% to 1.71%, and their filter criteria were: 1) affected in both 
strands of the original DNA template, 2) the total number of mutant reads from both strands 
was at least four.  
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Figure 4 Validation of rare allele quantification of KRAS subtype mutation G12D by digital PCR assay. 
The KRAS subtype mutation G12D was detected with a Custom Taqman SNP Genotyping Assay on the QuantStudio 3D Digital PCR system (Life Technologies). 
Each sample represents a mutant allelic fraction to wild-type genomic DNA background. All the samples were analyzed using QuantStudio 3D AnalysisSuite Cloud 
Software with the relative quantification module and absolute quantification module. 
A) No DNA template control. Absolute KRAS G12D was 0.07 copy/μL. 
B) Negative control with KRAS wild-type sample. Absolute KRAS G12D was 0.07 copy/μL. 
C) Positive control with KRAS mutation G12D (sample 47). Absolute mutation target was 422.3 copies/μL. Mutation allele frequency was 65.8% (95% confidence 
interval: 62.9% - 68.8%). 
Figure 4 D-I show allele frequencies of KRAS G12D for sample 23 (3.9%), sample 30 (2.1%), sample 34 (1.8%), sample 39 (0.81%), sample 55 (2.1%) and sample 
64 (1.9%). 
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Figure 5 Validation of rare allele quantification of KRAS subtype mutation G12V by digital PCR assay. 
The KRAS subtype mutation G12V was detected with a Custom Taqman SNP Genotyping Assay on the QuantStudio 3D Digital PCR system (Life Technologies). 
Each sample represents a mutant allelic fraction to wild-type genomic DNA background. All the samples were analyzed using QuantStudio 3D AnalysisSuite Cloud 
Software with the relative quantification module and absolute quantification module. 
A) No DNA template control. Absolute KRAS G12V was 0.07 copy/μL. 
B) Negative control with KRAS wild-type sample. Absolute KRAS G12V was 0.06 copy/μL. 
C) Positive control with KRAS mutation G12V (sample 45). Absolute mutation target was 161.7 copies/μL. Mutation allele frequency was 46.8% (95% confidence 
interval: 44.0% - 49.8%). 
Figure 5 D-I show allele frequencies of KRAS G12V: sample 12 (2.1%), sample 14 (3.4%), sample 43 (6.4%), sample 65 (1.2%), sample 74 (5.6%) and sample 86 
(3.0%). 
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Figure 6 Validation of rare allele quantification of KRAS subtype mutation G12R by digital PCR assay. 
The KRAS subtype mutation G12R was detected with a Custom Taqman SNP Genotyping Assay on the QuantStudio 3D Digital PCR system (Life Technologies). 
Each sample represents a mutant allelic fraction to wild-type genomic DNA background. All the samples were analyzed using QuantStudio 3D AnalysisSuite Cloud 
Software with the relative quantification module and absolute quantification module. 
A) No DNA template control. Absolute KRAS G12V was 0.07copy/μL. 
B) Negative control with KRAS wild-type sample. Absolute KRAS G12R was 0.06 copy/μL. 
C) Positive control with KRAS mutation G12D (sample 44). Absolute mutation target was 72.6 copies/μL. Mutation allele frequency was 32.3% (95% confidence 
interval: 30.0% - 34.7%). 
D) Allele frequency of KRAS G12R: sample 26 (2.5%).  
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5.4.3 Survival analysis according to KRAS mutation status 
In the study, the median survival time of patients with wild-type KRAS was 26.2 months, 
longer than that of the patients with any KRAS G12 mutation (15.7 month, p =0.067,  
Figure 7A). The median survival time of patients with KRAS mutant subtype were 11.9 
months for G12V, 16.5 months for G12R and 19.6 months for G12D, respectively (p 
=0.0197, Figure 7B). The median survival time among patients with or without mutations 
in SMAD4 or TGFBR2 was 14.1 and 20.8 months, respectively. However, the difference 
was not statistically significant (p =0.138, Figure 7C). Moreover, we did not find a 
significant difference of survival time between patients with or without TP53 mutations (p 
=0.391, Figure 7D). 
 
Figure 7 Overall survival analyses by the Kaplan-Meier method for pancreatic ductal 
adenocarcinoma patients restricted to T3 stage. (A) Overall survival by KRAS mutation status. (B) 
Overall survival by KRAS mutation subtype. (C) Overall survival by mutation status in TGF-β 
signaling pathway genes (SMAD4 or TGFBR2). (D) Overall survival by TP53 mutation status. 
 
5.4.4 Association between tobacco smoking and genetic alterations  
Tobacco smoking was associated with a greater frequency of transversion variants 
(OR=5.7), rather than transition variants (OR=0.7) (Table 8).
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Table 8 Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for G:C>T:A transversions, G:C>C:G transversions, total transversions, and total 
transitions in pancreatic ductal adenocarcinoma (PDAC) in association with tobacco smoking a 
 
 G:C>T:A G:C>C:G Transversions Transitionsb 
 No Yes OR (95% CI) No Yes OR (95% CI) No Yes OR (95% CI) Low High  OR (95% CI) 
Never-smoker 10 3 1.0 12 2 1.0 7 6 1.0 6 7 1.0 
Ever-smoker 32 11 2.3 (0.4, 11.6) 32 11 2.5 (0.4–14.9) 15 28 5.7 (1.2–27.8) 20 23 0.7 (0.2–2.9) 
 
aDerived from logistic regression model, adjusted for age and sex. One case was excluded due to a lack of tumor stage information; 16 cases were excluded due to a 
lack of smoking information. 
bTransitions: at 50% cutoff, <3 total transitions, low frequency; ≥3 total transitions, high frequency.
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6 DISCUSSION 
6.1 EPIDEMIOLOGICAL CONSIDERATIONS 
6.1.1 Study design 
The definition of epidemiology involves the study of the distribution and determinants of 
disease frequency in human populations (155). Epidemiologic research is constituted of 
several types of study designs, including experimental studies and observational studies. 
Ethics and cost limit most of the experimental studies; therefore most of epidemiologic 
studies are observational. In principle, there are two main types of observational studies, 
including cohort and case-control studies.  
6.1.1.1 Cohort study 
Broadly, cohort study is defined as any designated group of individuals who are followed or 
traced over a period of time (156), and a cohort study can be used to estimate average risks 
and rates (157). A prominent advantage of cohort study, compared to case-control study, is 
less prone to selection or recall bias. But, cohort studies are usually more expensive and time 
consuming. However, the Swedish health care system provides a unique opportunity that 
facilitates the follow-up of cohort at reasonably low cost. The national registration number 
contains the date of birth and 4 additional digits, and it not only enables the linkage within the 
medical care system, but also allows the linkage with Total Population and other 
demographic registers. The follow-up of Study I and II was through the linkage to Swedish 
health and population registers, including the Cancer Register, Causes of Death Register, and 
Emigration Register. Study II is a prospective cohort study with clinical examination that 
could collect detailed exposure data and information on potential confounders from the 
baseline questionnaire. The precious detailed information and virtually complete follow-up 
enable us to study the association between poor oral hygiene (including number of teeth, 
dental plaque and oral mucosal lesions) and the risk of pancreatic cancer. 
In Study I, the exposure information, namely the HCV or HBV infection data, were 
identified from a nationwide register that might have minimized the possibility of exposure 
misclassification. To estimate relative risks, standardized incidence ratios and hazard ratios 
were calculated. Of note, one limitation in Study I, a register-based cohort, is lack of detailed 
information of potential confounding factors, such as smoking. To address the potential 
concern of confounding by smoking, the relative risks of lung cancer were also estimated.        
6.1.1.2 Nested case-control study 
Study III is a case-control study nested within the EPIC cohort study, with the control group 
selected by sampling randomly from a well-defined source population. A nested case-control 
study combines advantages from both cohort and case-control studies. The purpose to 
conduct a nested case-control study is usually that additional information besides already 
available data is required. However, the cost is too high to obtain this information for the 
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entire cohort. For example in Study III, it is impossible to perform the serologic 
measurements for half a million people in the EPIC cohort.  
6.1.1.3 Case-only study 
Study IV is a case-only study that includes all operated cases in the Stockholm pancreatic 
cancer case-control study. A case-only design can be used for multiple purposes, for instance, 
to evaluate gene-gene and gene-environment interaction in disease etiology, to scan for the 
contribution of complex genotypes, and to assess heterogeneity of outcomes (157). In Study 
IV, by using this approach, we have identified the molecular alterations in the selected 
cancer-related genes in PDAC in Sweden. We then explored the associations between the 
identified genetic alterations (transition and transversion variants) and environmental 
exposures (e.g. tobacco smoking). We have also examined the prognostic heterogeneity 
according to different genetic alterations (e.g. KRAS mutations, TP53 mutations). 
6.1.2 Bias 
6.1.2.1 Selection bias 
Selection bias is defined as ‘distortions that result from procedures used to select subjects and 
from factors that influence study participation’ (157). Selection bias can occur in a cohort 
study, for example due to loss to follow-up. However, in Study I and II, our case 
identification was conducted through the linkage to the Cancer Register, which has an almost 
98% completeness of coverage. Information for censoring of follow-up was further derived 
from Causes of Death Register and Emigration Register which have also a virtually complete 
coverage. Selection bias can also arise in a cohort study when identification of exposed or 
unexposed individuals is associated with the possibility of developing the outcome of interest. 
In order to minimize the influence of this selection bias, sensitivity analysis was performed 
by excluding the first 6 months of follow-up in Study I, and by excluding the first 2 years of 
follow-up in Study II. In a case-control study, selection bias can occur if the controls are not 
representative of the population that cases originate from. The Study III which used a nested 
case-control study design suffered little from this bias, given that controls were randomly 
selected from the source population by a density-sampling method.  
6.1.2.2 Information bias 
Information bias can be introduced by measurement errors, e.g. errors in the measurement of 
exposure or outcome (157). Errors in the measurement are usually called classification error 
or misclassification. Misclassification of subjects for either exposure or outcome can be 
differential or non-differential (156), based on whether or not the misclassification is related 
with outcome or exposure. Much of discussion in misclassification has a focus on binary 
variable. The effects from differential misclassification can be bi-directional (overestimate or 
underestimate a true effect), whereas the bias from non-differential misclassification tends to 
dilute a true effect. In our studies, it is highly unlikely that the misclassification of the 
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exposure of interest was associated with the ascertainment of pancreatic cancer (study 
outcome).  
However, non-differential misclassification might occur in our studies. First of all, there 
could be non-differential misclassification of the outcome in Study I to III, due to the 
difficulties in the diagnosis of pancreatic cancer. In Study I and II, pancreatic cancer cases 
were identified from the Cancer Register, in which not all cases were histopathologically 
verified. There is also a concern of underreporting of pancreatic cancer due to the rapid 
progression of this malignancy and the Swedish Cancer Register does not include death-
certificate-only cases. Thus, a sensitivity analysis was performed with additional inclusion of 
death-certificate-only pancreatic cancer cases from the Causes of Death Register, and the 
results did not alter substantially. In Study III, a combined approach was applied to ascertain 
pancreatic cancer cases.  
The non-differential misclassification of exposure (dichotomous variable) may bias the 
association towards null. In Study I, the HCV/HBV infection information was obtained from 
a parallel notification system, and it is estimated that approximately 75-80% of HCV 
infections are diagnosed. However, unknown infection still may exist. In addition, a resolved 
infection could occur among a small portion of the infected patients, either spontaneously or 
after treatment. This would lead to an underestimation of the pancreatic cancer risk in the 
HCV and HBV cohort. In Study II, the oral health status indicators, including tooth number, 
dental plaque status and presence of oral mucosal lesions, might have changed during the 
follow-up period. However, compared to the self-reported information from other studies, the 
oral hygiene information obtained from clinical dental examination was more accurate and 
would have reduced the non-differential misclassification of the exposures. In Study III, the 
serostatus of H. pylori infection might have been misclassified among cases and controls, due 
to unfavorable environment associated H. pylori clearance after long-term exposure of H. 
pylori infection and chronic gastric inflammation (158, 159). Therefore, a true positive 
association between H. pylori infection and pancreatic cancer might be biased towards null. 
In addition, we used serum pepsinogens I and II to determine the presence of chronic corpus 
atrophic gastritis, rather than using the ‘gold standard’ of the diagnosis based on 
histopathological examination. This could also introduce misclassification. However, there 
was no report that pancreatic cancer might influence pepsinogen levels. Furthermore, we 
determined O blood type through ABO rs505922. Although it has high linkage 
disequilibrium with rs8176719, it still could not fully replace rs8176719. Thus, the 
genotyping measurement error may arise, which would lead to non-differential 
misclassification of O and non-O blood type in Study III.  
6.1.3 Confounding 
Confounding, a confusion of effects (157),  is a central issue for observational studies (160). 
Since the true association between exposure and outcome would be distorted by confounding, 
the confounders should be controlled, for example, in the study design stage, the analysis 
stage, or in a combination of the two approaches (160). One of the most prominent 
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limitations in the register-based studies is the lack of detailed information on the potential 
confounders. In Study I, potential confounding factors, including chronic obstructive 
pulmonary disease (as a proxy of smoking), diabetes mellitus, chronic pancreatitis and 
alcohol-related disease (as a proxy of heavy alcohol consumption) were identified from the 
Inpatient Register, and were further adjusted in Cox regression models. In addition, we 
indirectly estimated the smoking prevalence by calculating the relative risks for lung cancer. 
Smoking was more common in the HCV cohort than in the general population, given that we 
found a doubled risk of lung cancer in the HCV cohort. The relative risks for both lung 
cancer and pancreatic cancer were similar in either crude or fully-adjusted model, implying 
that smoking would not bias our finding entirely. If the finding was explained only by 
smoking, the HR of lung cancer in the HCV cohort should have been higher, given the fact 
that the relative risk of lung cancer was around 10 among smokers compared with non-
smokers (161), whereas the corresponding figure was only 2 for pancreatic cancer (24). 
Moreover, according to Walker’s finding (162), the effect of confounding is relatively small, 
even if both the relationships between exposure and covariate, as well as covariate and 
outcome, are strong. For instance, in order to completely bias an exposure effect of 1.4 by 
confounding, it requires the strengths of the association of confounder-exposure and 
confounder-outcome to be greater than 3. In Study II, we lacked data of BMI or waist-to-hip 
ratio. Besides, based on the limited information of alcohol consumption (low vs high), 
residual confounding might be present. However, considering their small effects on 
pancreatic cancer risk, these factors are unlikely to completely bias our findings.  
6.2 STRENGTHS OF THE STUDIES 
The shared strengths of Study I to III include a prospective cohort design (or based on a 
prospective cohort study), relatively large study population, and high completeness of follow-
up. The special advantage for Study I is the available information from the nationwide 
documentation of HCV/HBV notifications. Of note for Study II, strengths include the 
professional clinical oral examination by one doctor for all participants, and the availability of 
information about potential confounders from baseline questionnaire. The important points of 
Study III include the access to prediagnostic blood samples and the availability of detailed 
information on potential confounding factors. For Study IV, we took advantage of the AMP-
based NGS and found that this method is applicable for profiling tumor variants, even for 
clinical samples of low tumor cellularity. 
6.3 INTERPRETATIONS OF FINDINGS 
6.3.1 Pancreatic cancer risk assessment 
6.3.1.1 HCV or HBV infection and pancreatic cancer risk  
In Study I, we found a doubled risk of pancreatic cancer among HCV cohort compared with 
the Swedish general population. The excessive risk was consistent across strata by sex or 
duration of infection. Although attenuated association was observed after adjustment for 
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potential confounding factors, the finding still supports the hypothesis that HCV infection 
may be associated with an elevated pancreatic cancer risk. Moreover, we found a moderate 
excessive risk of pancreatic cancer among HBV-infected patients by different statistical 
approaches, however the size of the study cohort and the observed case numbers were too 
small to draw a sound conclusion.  
It is still unclear about the biological mechanisms underlying the observed association 
between HCV and pancreatic cancer. Previous research illustrated that the pancreas is a 
remote location for hepatitis virus inhabitation and replication, as the pancreas and liver share 
common blood vessels and ducts (163). Immune response may cause chronic inflammation in 
the targeted organs after long-term persistent infection with HCV. Therefore, acting as a 
biological agent, HCV may indirectly play a role in inflammation-associated pancreatic 
carcinogenesis, through formation of an inflammatory microenvironment with a high 
concentration of growth factors and cytokines. As for the HBV infection, prior evidence 
suggested that HBV may replicate in the pancreas. A potential hypothesis proposes that a 
long period of chronic HBV infection, concurrent with damage of pancreatic epithelial cells, 
leads to an inflammatory response that consequently plays a role in the pancreatic cancer 
development. 
To date, a few epidemiologic studies have examined the association between HCV/HBV and 
pancreatic cancer risk, whereas the results are still inconsistent. A US veteran cohort study 
showed a significant association between HCV and pancreatic cancer. However, the positive 
association was attenuated after adjusting for potential confounding factors (164). A case-
control study demonstrated that the prevalence of HCV antibodies was not significantly 
higher among pancreatic cancer patients (1.5%) compared with controls (1%), however, a 
significantly higher prevalence of past exposure to HBV but not current or chronic infection, 
was observed among pancreatic cancer patients compared with control subjects (163). On the 
other hand, the REVEAL-HBV cohort study and a Chinese case-control study reported an 
elevated pancreatic cancer risk associated with chronic HBV infection (165, 166). In two 
meta-analysis studies, the authors found that chronic HCV and HBV infection increases 
pancreatic cancer risk, whereas past exposure to HBV may not be related to pancreatic cancer 
risk (167, 168).  
6.3.1.2 Poor oral hygiene and pancreatic cancer risk 
In Study II, our findings provide evidence to support the hypothesis that poor oral hygiene 
plays an important role in the development of pancreatic cancer. Although without statistical 
significance, the point estimates indicated a possible association between baseline tooth 
number and pancreatic cancer risk. Besides, presence of dental plaque is found to be 
associated with an increased pancreatic cancer risk. In addition, we found positive 
associations between pancreatic cancer and presence of oral mucosal lesions, including 
Candida- or denture-related oral mucosal lesions, and tongue lesions. To the best of our 
knowledge, this is the first prospective cohort study to explore the association between oral 
mucosal lesions and pancreatic cancer risk. 
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Increased production of carcinogenic nitrosamines and systemic inflammation are considered 
as potential plausible mechanisms. One poor oral hygiene indicator, i.e. a high amount of 
dental plaque, may be served as a reservoir for oral bacteria. In the nitrosamine-related 
hypothesis, individuals with poor oral hygiene may contain an abundance of nitrate-reducing 
bacteria, which will facilitate the formation of nitrosamines (169, 170). Nitrosamines have a 
carcinogenetic effect, and can induce and promote pancreatic cancer development (120, 121). 
On the other hand, an alternative hypothesis has been proposed. Poor oral hygiene may 
promote the formation of an environment in which certain oral pathogens, namely ‘keystone 
pathogens’, such as P. gingivalis, are able to evade host immune response and impair innate 
immunity. Moreover, the colonization of ‘keystone pathogens’ may also contribute to form a 
local environment that is favorable for bacterial overgrowth, which subsequently can mediate 
the microbial community and strengthen the conversion from a symbiotic state to a dysbiotic 
state (115, 116). This cascade of events may lead to a systemic inflammation state, which 
may play an important role in pancreatic cancer development. The inflammation state may 
promote the formation of a microenvironment that favors the accumulation of genetic 
alterations, initiates pancreatic carcinogenesis and fosters tumor development (110, 117).  
6.3.1.3 Helicobacter pylori infection and pancreatic cancer risk 
In Study III, a nested case-control study within a large European prospective cohort study, 
we observed no association between H. pylori infection (indicated by either H. pylori 
seropositivity or CagA seropositivity, or a combination of both) and pancreatic cancer risk. 
This null association remained unchanged in a combined analysis by including ABO blood 
type. On the other hand, based on a small sample size, our findings provided some support 
that chronic corpus atrophic gastritis, defined by serological pepsinogen levels, might be 
associated with pancreatic cancer risk, especially among the H. pylori seronegative 
individuals. 
In the long period of H. pylori colonization in the stomach, the pathogenesis process usually 
goes through superficial gastritis, chronic atrophic gastritis, metaplasia and dysplasia (171). 
The development of multifocal atrophic gastritis causes hypo- or achlorhydria and basal 
hypergastrinemia due to the loss of parietal cells. The low acid environment in the stomach 
subsequently entails the bacterial overgrowth and promotes intragastric N-nitrosation 
catalyzation (172); through circulation in blood stream, the N-nitrosamines may be 
transported and activated in the pancreas, and may foster carcinogenesis in the pancreas. 
Other supporting evidence for this hypoacidity hypothesis comes from a register-based 
Swedish study, in which an increased pancreatic cancer risk was found in gastric ulcer 
patients, rather than the duodenal ulcer patients (173). Duodenal ulcer is associated with 
antral colonization of H. pylori and hyperchlorhydria, while gastric ulcer is related to corpus 
colonization of H. pylori with normo- or hypochlorhydria. In addition, long period hypo- or 
achlorhydria was characterized in pernicious anemia patients, and in these patients an 
excessive risk of pancreatic cancer has also been reported (174, 175).  
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A Finnish study on male smokers found that neither atrophic gastritis (defined by serologic 
pepsinogen level) nor histologically confirmed atrophic gastritis was associated with 
subsequent pancreatic cancer risk (176). However, in our study, although it was based on a 
small sample size, we found a positive association between chronic corpus atrophic gastritis 
and pancreatic cancer in the stratum seronegative for both H. pylori and CagA, but not in the 
stratum seropositive for H. pylori or CagA. One possible explanation is that chronic corpus 
atrophic gastritis might be more severe among the stratum seronegative for both H. pylori and 
CagA. Previous studies have shown that long-term advanced chronic corpus atrophic gastritis 
might lead to clearance of H. pylori colonization of the stomach mucosa, and subsequently 
lead to lower antibodies against the bacterium (158, 159). Nevertheless, given the small 
number in this stratum, we still cannot rule out the possibility that the observed positive 
association was due to chance. Future studies are merited to verify this association, due to the 
limitation of this study, and if confirmed, to further investigate the underlying mechanisms.     
6.3.2 Variant profiling in PDAC  
In Study IV, we found that the AMP-based assay can achieve analytically sensitive variant 
profiling in PDAC given sufficient sequencing depth. Our findings revealed a unique tumor 
variant profile, including dominance of KRAS mutations, majority in point mutations, and 
minority in insertions or deletions. A number of target enrichment assays, deep sequencing 
methods as well as variant calling algorithms have been designed and developed (177). 
However, it is still a challenge to identify true variants from background noises, which 
generally limits the analytical performance of these methods. In this study, we used the AMP-
based method to enrich the targeted regions, and sequenced the targeted regions with a high 
depth of coverage. In a performance analytical test using a standard DNA reference, the 
findings elucidated that the AMP-based assay can detect tumor variants with allele 
frequencies as low as 1%, given sufficient sequencing depth. In addition, in the clinical 
PDAC samples, the detected KRAS mutations were completely confirmed by Sanger 
sequencing for high-mutant-allele-frequency samples, and also by allele-specific PCR and 
digital PCR for low-mutant-allele-frequency samples. The supportive evidence from these 
validation studies suggested that the AMP-based method is reliable for detecting tumor 
variants at a broad range.  
In Study IV, we also found that patients with KRAS mutant G12V subtype had a worse 
prognosis, and the association remained largely unchanged after separate adjustment for 
smoking, chemotherapy treatment or TP53 mutation status. Due to variations in study design, 
sample size, source population and tumor stages, the effects of KRAS mutations on overall 
survival of PDAC remain controversial (178-181). However, the aggressive biological 
behavior of G12V subtype was corroborated in earlier studies on other cancer types, 
including colorectal and lung cancers (182-184). Moreover, in vitro studies demonstrated that 
the GTPase activity of G12V is lower than G12D and wild-type KRAS, which can lock the 
mutant KRAS protein in the GTP-bound active state for a long period of time (185, 186). 
However, larger cohort studies are warranted to confirm these findings. Furthermore, our data 
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indicated that smoking is associated with transversion variants in PDAC. Previous studies 
indicated that KRAS and TP53 mutations in pancreatic cancer patients are more common in 
smokers than in non-smokers (187, 188). However, some studies disproved these findings 
(189, 190). One study demonstrated that transition variants were 24% more common among 
smokers compared to non-smokers, while transversion variants were 53% more common in 
smokers (191). Larger studies are needed to confirm this finding and to further explore the 
associations between other environmental risk factors and the observed mutations in PDAC.  
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7 CONCLUSIONS 
• HCV infection may be related to a higher pancreatic cancer risk, however, it requires 
larger cohort studies to verify this observed association. 
 
• Poor oral hygiene, indicated by presence of dental plaque and oral mucosal lesions, is 
related to an elevated pancreatic cancer risk. This finding supports the hypothesis that 
poor oral hygiene has an important role in the development of pancreatic cancer.  
 
• H. pylori infection is not related with pancreatic cancer risk in the western European 
populations. However, the suggested positive association between chronic corpus 
atrophic gastritis and pancreatic cancer warrants larger independent studies for 
verification, and, if confirmed, further studies are merited to explore the underlying 
mechanisms.   
 
• The AMP-based next-generation sequencing is sensitive and accurate method for 
direct variant profiling of clinical pancreatic cancer samples. Using this method, we 
elucidated that in PDAC patients, KRAS mutant subtype G12V is associated with 
inferior survival, and that transversion variants are more common among smokers. 
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8 FUTURE PERSPECTIVES 
Although progress has been made in recent decades in pancreatic cancer research, much 
remains unresolved for this malignancy, particularly as it is always diagnosed at an advanced 
and non-curative stage and with a dismal prognosis. In this thesis, we contributed somewhat 
to the further understanding of the etiology of pancreatic cancer with regards to potential 
infectious agents and poor oral hygiene. We have also developed a method for variant 
profiling of candidate genes in PDAC using AMP-based NGS.  
For the potential association between infectious agents and pancreatic cancer risk, further 
studies with more complete information on potential confounding factors are warranted to 
solidify the associations. Further studies with larger sample sizes are also warranted to verify 
whether severe gastric atrophy contributes to pancreatic carcinogenesis. In addition, the 
potential pancreatic pathogenic bacteria and/or fungi from dental plaque and oral mucosal 
lesions need to be identified in future studies. 
In Study IV, some targeted regions had poor depth of coverage, for instance high GC content 
in the TERT promoter and FOXL2. Therefore, optimization is warranted for a better coverage 
of the GC-rich regions; for example, future experiments should be designed to include PCR 
additives such as DMSO and betaine. Furthermore, small amounts of DNA materials (e.g. 
those obtained from EUS guided-fine needle aspiration), should be applied to the AMP-based 
assays to test a panel of key targeted genes simultaneously, and make the AMP-based NGS 
method an attractive assay to identify genetic alterations in the various pancreatic lesions, e.g. 
pancreatic intraepithelial neoplasia, IPMN. 
Recently, detection of circulating tumor DNA (ctDNA), a ‘liquid biopsy’ technology, has 
emerged as a new generation of biomarker detection method. It can be used for the detection 
of genetic alterations that lead to initiation and progression of human cancers. It has attracted 
increasing attention as it is a non-invasive detection method. However, it is limited by the 
difficulty to identify the trace amount of cancer-specific nucleic acids among an 
overwhelming wild-type background. Future studies should attempt to detect mutations, such 
as KRAS mutations on codon 12, 13 and 61, in ctDNA samples of PDAC patients using 
AMP-based assay in a longitudinal study, and aim to expand the utilization of ctDNA for 
early detection, as well as for monitoring recurrence of the tumor after treatment.       
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